SA PRO
Free Account
Rocket Pharmaceuticals, Inc.RCKTNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 72% recommend buying.

Consensus Rating
Buy
18 analysts·Moderate coverage
72%
Rating Distribution
Strong Buy
00%
Buy
1372%
Hold
422%
Sell
16%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 72% higher.

Bear Case
$5.00
+44%
Consensus
$6.00
+72%
Bull Case
$7.00
+101%
Price Range18 analysts
Low
Consensus
High
$5.00
$7.00
Current Target
Current Price
$3.48
Upside to Target
$2.52

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 8, 2026Morgan Stanley
Rocket Pharmaceuticals price target lowered to $5 from $7 at Morgan Stanley
Target:$5.00
+28.5%from $3.89
Oct 3, 2025Leerink Partners
Rocket Pharmaceuticals price target lowered to $7 from $9 at Leerink
Target:$7.00
+114.7%from $3.26
May 28, 2025Goldman Sachs
Goldman downgrades Rocket to Sell on 'surprising and concerning' update
Target:$2.00
-19.4%from $2.48
May 28, 2025Jefferies
These Analysts Slash Their Forecasts On Rocket Pharmaceuticals
Target:$2.50
+1.0%from $2.48
Dec 30, 2024Wedbush
Rocket Pharmaceuticals initiated with an Outperform at Wedbush
Target:$32.00
+166.0%from $12.03
Nov 11, 2024Canaccord Genuity
Rocket Pharmaceuticals (RCKT) PT Raised to $39 at Canaccord Genuity
Target:$39.00
+128.2%from $17.09
Sep 18, 2024Canaccord Genuity
Canaccord Genuity Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT)
Target:$38.00
+74.3%from $21.80
Sep 17, 2024Morgan Stanley
Morgan Stanley on Rocket Pharmaceuticals (RCKT): 'we are encouraged by rapid enrollment'
Target:$45.00
+112.5%from $21.18
Apr 2, 2024Goldman Sachs
Goldman Sachs Starts Rocket Pharmaceuticals (RCKT) at Neutral, 'Four Potential Launches in Next 2Y but DD Oppy May be Overstated'
Target:$39.00
+46.0%from $26.72
Oct 3, 2022Raymond James
Raymond James Maintains Outperform on Rocket Pharmaceuticals, Raises Price Target to $34
Target:$34.00
+113.0%from $15.96
Aug 9, 2022Raymond James
Raymond James Maintains Outperform on Rocket Pharmaceuticals, Raises Price Target to $24
Target:$24.00
+58.2%from $15.17
Aug 12, 2021UBS
Rocket Pharmaceuticals (RCKT) PT Lowered to $69 at UBS
Target:$69.00
+124.0%from $30.80

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance